{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:54:27Z","timestamp":1785545667527,"version":"3.56.0"},"reference-count":31,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019832","name":"Gal\u00e1pagos","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019832","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,12,19]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This post hoc analysis of the FINCH 1\u20133 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02889796\">NCT02889796<\/jats:ext-link>,  <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02873936\">NCT02873936<\/jats:ext-link> and <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02886728\">NCT02886728<\/jats:ext-link>) studies assessed specific effects of filgotinib on pain control and their relationship with other aspects of efficacy in patients with rheumatoid arthritis (RA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Assessments included: residual pain responses of \u226410\u2009and \u226420\u2009mm on a 100\u2009mm visual analogue scale (VAS); the proportion of patients who achieved VAS pain responses in addition to remission or low disease activity by Disease Activity Score-28 with C-reactive protein (DAS28-CRP) or Clinical Disease Activity Index (CDAI) criteria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Across studies, filgotinib reduced pain from week 2, with responses sustained throughout the studies. In FINCH 1, at week 24, 35.8%, 25.0%, 24.6% and 11.6% of patients in the filgotinib 200\u2009mg, filgotinib 100\u2009mg, adalimumab and placebo arms (each plus methotrexate) achieved VAS pain \u226420\u2009mm in addition to DAS28-CRP remission; 26.3%, 17.9%, 17.2% and 7.6% achieved VAS pain \u226410\u2009mm in addition to DAS28-CRP remission. A similar pattern was seen for CDAI remission. Time during which VAS pain was \u226410\u2009or \u226420\u2009mm was longest with filgotinib 200\u2009mg and comparable between adalimumab and filgotinib 100\u2009mg. Similar findings were reported for filgotinib in FINCH 2 and 3.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In all RA populations studied, pain improvements occurred from week 2 and were sustained over time. In FINCH 1, filgotinib 100\u2009mg provided similar pain amelioration to adalimumab, whereas filgotinib 200\u2009mg resulted in greater pain improvement and higher proportion of patients with residual pain \u226410\u2009or \u226420\u2009mm and meeting DAS28-CRP remission criteria.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-003839","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T23:40:11Z","timestamp":1710286811000},"page":"e003839","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Impact of filgotinib on pain control in the phase 3 FINCH studies"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02889796","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02873936","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02886728","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02889796","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02873936","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02886728","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-6167","authenticated-orcid":false,"given":"Peter C","family":"Taylor","sequence":"first","affiliation":[{"name":"Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2571-788X","authenticated-orcid":false,"given":"Peter","family":"Nash","sequence":"additional","affiliation":[{"name":"School of Medicine, Griffith University, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1479-5302","authenticated-orcid":false,"given":"Janet","family":"Pope","sequence":"additional","affiliation":[{"name":"Department of Medicine, Western University, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Pongratz","sequence":"additional","affiliation":[{"name":"Asklepios Klinikum Bad Abbach, Bad Abbach, Germany"},{"name":"Faculty of Medicine, University of Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8845-4274","authenticated-orcid":false,"given":"Bruno","family":"Fautrel","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, APHP \u2013 Sorbonne University, GH Piti\u00e9 Salp\u00eatri\u00e8re, Paris, France"},{"name":"Pierre Louis Institut of Epidemiology and Public Health, INSERM UMRS 1136, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3395-4412","authenticated-orcid":false,"given":"Rieke","family":"Alten","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Global Medical Affairs Research, Gilead Sciences, Inc, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangbang","family":"Rao","sequence":"additional","affiliation":[{"name":"Biostatistics, Gilead Sciences, Inc, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"de Vries","sequence":"additional","affiliation":[{"name":"Research and Development, Clinical Research, Galapagos BV, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter-Jan","family":"Stiers","sequence":"additional","affiliation":[{"name":"Biostatistics, Galapagos NV, Mechelen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Watson","sequence":"additional","affiliation":[{"name":"Medical Affairs, Galapagos Biotech Ltd, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3432-3073","authenticated-orcid":false,"given":"Rene","family":"Westhovens","sequence":"additional","affiliation":[{"name":"Rheumatology, UZ Leuven, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"2025090312313691000_10.1.e003839.1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.680043","article-title":"The therapeutic landscape of rheumatoid arthritis: current state and future directions","volume":"12","author":"Shams","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025090312313691000_10.1.e003839.2","first-page":"231","article-title":"Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response","volume":"8","author":"Kosinski","year":"2002","journal-title":"Am J Manag Care"},{"key":"2025090312313691000_10.1.e003839.3","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1177\/147323001003800402","article-title":"Patient perceptions concerning pain management in the treatment of rheumatoid arthritis","volume":"38","author":"Taylor","year":"2010","journal-title":"J Int Med Res"},{"key":"2025090312313691000_10.1.e003839.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.64"},{"key":"2025090312313691000_10.1.e003839.5","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/acr.22824","article-title":"Unraveling patient-preferred health and treatment outcomes in early rheumatoid arthritis: a longitudinal qualitative study","volume":"68","author":"van der Elst","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312313691000_10.1.e003839.6","article-title":"The perspective of patients with early rheumatoid arthritis on the journey from symptom onset until referral to a rheumatologist","volume":"3","author":"De Cock","year":"2019","journal-title":"Rheumatol Adv Pract"},{"key":"2025090312313691000_10.1.e003839.7","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1016\/S2665-9913(23)00094-2","article-title":"Pain in the joints and beyond; the challenge of rheumatoid arthritis","volume":"5","author":"Taylor","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2025090312313691000_10.1.e003839.8","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/14397595.2017.1416940","article-title":"Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review","volume":"28","author":"Ishida","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2025090312313691000_10.1.e003839.9","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001146","article-title":"One in five patients with rapidly and persistently controlled early rheumatoid arthritis report poor well-being after 1 year of treatment","volume":"6","author":"Van der Elst","year":"2020","journal-title":"RMD Open"},{"key":"2025090312313691000_10.1.e003839.10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200758"},{"key":"2025090312313691000_10.1.e003839.11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/rheumatology\/keac213","article-title":"New indicator for discordance between patient-reported and traditional disease activity outcomes in patients with early rheumatoid arthritis","volume":"62","author":"Pazmino","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312313691000_10.1.e003839.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360601"},{"key":"2025090312313691000_10.1.e003839.13","first-page":"86","article-title":"World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials","volume":"41","author":"Boers","year":"1994","journal-title":"J Rheumatol Suppl"},{"key":"2025090312313691000_10.1.e003839.14","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1080\/14656566.2021.1940136","article-title":"Does opioid-based pharmacotherapy have a place in rheumatoid arthritis therapy","volume":"22","author":"Pazmino","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"2025090312313691000_10.1.e003839.15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093396","article-title":"Behavioral, biochemical and electrophysiological changes in spared nerve injury model of neuropathic pain","volume":"21","author":"Guida","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025090312313691000_10.1.e003839.16","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1002\/jnr.24324","article-title":"Red nucleus interleukin-1beta evokes tactile allodynia through activation of JAK\/STAT3 and JNK signaling pathways","volume":"96","author":"Guo","year":"2018","journal-title":"J Neurosci Res"},{"key":"2025090312313691000_10.1.e003839.17","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000158"},{"key":"2025090312313691000_10.1.e003839.18","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8060831","article-title":"Achieving pain control in rheumatoid arthritis with baricitinib or adalimumab plus methotrexate: results from the RA-BEAM trial","volume":"8","author":"Taylor","year":"2019","journal-title":"J Clin Med"},{"key":"2025090312313691000_10.1.e003839.19","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001994","article-title":"Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy","volume":"8","author":"Taylor","year":"2022","journal-title":"RMD Open"},{"key":"2025090312313691000_10.1.e003839.20","first-page":"848","article-title":"Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month phase 3 ORAL scan study","volume":"38","author":"Strand","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312313691000_10.1.e003839.21","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-2037-1","article-title":"Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT","volume":"21","author":"Strand","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025090312313691000_10.1.e003839.22","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-022-02813-x","article-title":"Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial","volume":"24","author":"Bergman","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2025090312313691000_10.1.e003839.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219214"},{"key":"2025090312313691000_10.1.e003839.24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9055"},{"key":"2025090312313691000_10.1.e003839.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219213"},{"key":"2025090312313691000_10.1.e003839.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"2025090312313691000_10.1.e003839.27","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24596"},{"key":"2025090312313691000_10.1.e003839.28","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-016-0581-0","article-title":"Non-inflammatory causes of pain in patients with rheumatoid arthritis","volume":"18","author":"Boyden","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"2025090312313691000_10.1.e003839.29","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.semarthrit.2020.10.008","article-title":"The JAK\/STAT pathway: a focus on pain in rheumatoid arthritis","volume":"51","author":"Simon","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312313691000_10.1.e003839.30","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1177-9","article-title":"Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study","volume":"18","author":"van Wesemael","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025090312313691000_10.1.e003839.31","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-016-0563-2","article-title":"The roles of cigarette smoking and the lung in the transitions between phases of preclinical rheumatoid arthritis","volume":"18","author":"Sparks","year":"2016","journal-title":"Curr Rheumatol Rep"}],"updated-by":[{"DOI":"10.1136\/rmdopen-2023-003839corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000}}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:31:48Z","timestamp":1756927908000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,3,12]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/rmdopen-2023-003839"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003839","relation":{"correction":[{"id-type":"doi","id":"10.1136\/rmdopen-2023-003839corr1","asserted-by":"object"}]},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}